Unlike CD19 in acute lymphoblastic leukemia (ALL), FLT3 is also expressed at lower levels in normal hematopoietic stem and progenitor cells (HSPCs), raising concerns about on-target, off-tumor toxicity for CAR-based therapies. Here, FLT3 is linked to acute lymphoblastic leukemia.